Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 3:1
Drug Approvals
4
NMPA:4
Drug Approvals
Clavulanate Potassium-Silicon Dioxide
- Product Name
- 克拉维酸钾-二氧化硅
- Approval Number
- H20140815
- Approval Date
- Oct 31, 2014
NMPA
Clavulanate Potassium-Silicon Dioxide
- Product Name
- 克拉维酸钾-二氧化硅
- Approval Number
- H20140814
- Approval Date
- Oct 31, 2014
NMPA
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 3
1 (25.0%)Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- CKD Bio Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT05804656
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- CKD Bio Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05428930
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- CKD Bio Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05382767
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- CKD Bio Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05292638
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
News
No news found